GPh 301

Drug Profile

GPh 301

Alternative Names: GPh-301

Latest Information Update: 18 Dec 2015

Price : $50

At a glance

  • Originator GEROPHARM
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Endocrine disorders

Most Recent Events

  • 18 Dec 2015 Preclinical trials in Endocrine disorders in Russia (unspecified route) (GEROPHARM pipeline, December 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top